These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19372579)

  • 1. Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix.
    Zhang Y; Zhao H; Asztalos S; Chisamore M; Sitabkhan Y; Tonetti DA
    Mol Cancer Res; 2009 Apr; 7(4):498-510. PubMed ID: 19372579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
    Chisamore MJ; Ahmed Y; Bentrem DJ; Jordan VC; Tonetti DA
    Clin Cancer Res; 2001 Oct; 7(10):3156-65. PubMed ID: 11595710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
    Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
    Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model.
    Lin X; Yu Y; Zhao H; Zhang Y; Manela J; Tonetti DA
    Carcinogenesis; 2006 Aug; 27(8):1538-46. PubMed ID: 16513679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.
    Murphy CS; Pink JJ; Jordan VC
    Cancer Res; 1990 Nov; 50(22):7285-92. PubMed ID: 2224859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer.
    Molloy ME; White BE; Gherezghiher T; Michalsen BT; Xiong R; Patel H; Zhao H; Maximov PY; Jordan VC; Thatcher GR; Tonetti DA
    Mol Cancer Ther; 2014 Nov; 13(11):2515-26. PubMed ID: 25205655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors.
    Rose-Hellekant TA; Skildum AJ; Zhdankin O; Greene AL; Regal RR; Kundel KD; Kundel DW
    Cancer Prev Res (Phila); 2009 May; 2(5):496-502. PubMed ID: 19401525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
    Pink JJ; Jordan VC
    Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
    Osipo C; Gajdos C; Liu H; Chen B; Jordan VC
    J Natl Cancer Inst; 2003 Nov; 95(21):1597-608. PubMed ID: 14600092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
    Riggio M; Polo ML; Blaustein M; Colman-Lerner A; Lüthy I; Lanari C; Novaro V
    Carcinogenesis; 2012 Mar; 33(3):509-18. PubMed ID: 22180571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and regulation of estrogen receptor beta in human breast tumors and cell lines.
    Vladusic EA; Hornby AE; Guerra-Vladusic FK; Lakins J; Lupu R
    Oncol Rep; 2000; 7(1):157-67. PubMed ID: 10601611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
    Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
    Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions.
    Pontiggia O; Rodriguez V; Fabris V; Raffo D; Bumaschny V; Fiszman G; de Kier Joffé EB; Simian M
    Breast Cancer Res Treat; 2009 Jul; 116(2):247-55. PubMed ID: 18622696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation.
    Fan M; Nakshatri H; Nephew KP
    Mol Endocrinol; 2004 Nov; 18(11):2603-15. PubMed ID: 15284335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas.
    Montecchia MF; Lamb C; Molinolo AA; Luthy IA; Pazos P; Charreau E; Vanzulli S; Lanari C
    J Steroid Biochem Mol Biol; 1999 Jan; 68(1-2):11-21. PubMed ID: 10215033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
    Lau KM; LaSpina M; Long J; Ho SM
    Cancer Res; 2000 Jun; 60(12):3175-82. PubMed ID: 10866308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models.
    Bhat KP; Lantvit D; Christov K; Mehta RG; Moon RC; Pezzuto JM
    Cancer Res; 2001 Oct; 61(20):7456-63. PubMed ID: 11606380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
    Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.